Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Tokai University Research: Clinical Tests Show That 'Cell-sheet Accelerating Technology' Offers Promising Treatment for Osteoarthritis of the Knee


News provided by

Tokai University

25 Mar, 2019, 10:39 GMT

Share this article

Share toX

Share this article

Share toX

HIRATSUKA CITY, Japan, March 25, 2019 /PRNewswire/ -- Researchers at Tokai University report in the journal npj Regenerative Medicine a regenerative medicine approach for treating osteoarthritis of the knee. The researchers led by Masato Sato, fabricated chondrocyte sheets—that have regenerative properties—on temperature-responsive culture dishes to treat partial-thickness defects in articular cartilage, tissue that is known to be difficult to regenerate.

Continue Reading
This image opens in the lightbox
tokai_fig_small

Osteoarthritis (OA) is a joint disease, caused by breakdown of the cartilage in the joint — cartilage is a 'biological lubricant' that contains no blood vessels or nerves, but mainly cells known as chondrocytes.  OA leads to the gradual loss of a human's mobility, thus negatively affecting a patient's quality of life. No cure exists for stopping OA progression. Chondrocyte implantation products are sometimes applied, but for OA of the knee, such implantation approaches are not effective. Now, Masato Sato, professor at the Tokai University School of Medicine, and colleagues have shown that an approach combining conventional surgery and chondrocyte cell-sheet transplantation is a promising therapy for OA of the knee.

The researchers had shown earlier that transplantation of chondrocyte sheets in animal models promoted cartilage repair, but such transplantations had never been applied to humans. Sato and colleagues first performed conventional surgery and then chondrocyte sheet-cell transplantation on eight patients with OA of the knee. 

The transplantations were autologous, meaning that material from the individual was used. This is both disadvantageous (healthy cartilage from another, albeit limited, area in the knee has to be sacrificed) and advantageous (no foreign material enters the body).  Because of the need for autologous material, it is unrealistic to perform the procedure more than two times on one and the same patient.

The result of the combined approach was assessed by various techniques, including X-ray imaging (before and after the procedure), magnetic-resonance imaging, arthroscopy and photoacoustic measurements of cartilage viscoelasticity.

The scientists point out a few limitations of their study. Only eight patients were treated, and although promising outcomes were recorded over the course of a 3-year observation period, longer-term observations are needed to fully assess the proposed combined therapy.

Because the therapy is a combination of different procedures, it is challenging to make it compliant with regulations — usually requiring clear evidence of the effect of every single intervention.  Quoting the researchers who worked on the Japan Agency for Medical Research and Development (AMED) grant program: "Although the method used in our clinical study is challenging for the regulatory authorities, we believe it is essential to continue investigating the outcomes in more patients with OA of the knee. Determining the true effectiveness of this therapy for OAK requires longer-term follow-up and strict comparative studies."

Following the favorable results of the clinical trials, the treatment developed by Sato and his group was approved by Japan's Ministry of Health, Labour and Welfare as an advanced medical treatment for osteoarthritis of the knee.

Background

Osteoarthritis

Osteoarthritis (OA), a type of joint disease, results from the breakdown of cartilage, the matrix-type material acting as a lubricant between the bones in a joint. Typical symptoms are joint pain and stiffness. Often, the symptoms develop over several years, and significantly affect daily life as it typically reduces a patient's mobility.

Masato Sato from Tokai University and colleagues have now suggested a treatment for OA of the knee, for which little to no cure exists. The procedure consists of conventional surgery aligning and stabilizing the bones in the joint, and then transplanting sheets of chondrocyte cells into the cartilage defects.  (Chondrocytes are the cells found in cartilage.). Initial outcomes of the study have been positive.

Reference

Masato Sato, Masayuki Yamato, Genya Mitani, Tomonori Takagaki, Kosuke Hamahashi, Yoshihiko Nakamura, Miya Ishihara, Ryo Matoba, Hiroyuki Kobayashi, Teruo Okano, Joji Mochida, Masahiko Watanabe. Combined surgery and chondrocyte cell-sheet transplantation improves clinical and structural outcomes in knee osteoarthritis. npj Regenerative Medicine 4, 4, 21 February 2019

DOI: 10.1038/s41536-019-0069-4

https://www.nature.com/articles/s41536-019-0069-4

Chondrocyte cell-sheet preparation (A) and combined surgery/transplantation approach for osteoarthritis of the knee (B).

About Tokai University

Tokai University is a private university established by Shigeyoshi Matsumae in 1942.

"Tokai" of "Tokai University" refers to the sea to the east of Asia, namely the Pacific Ocean, and symbolizes the desire to foster the kinds of big hearts, rich spirits, and broad perspectives symbolized by the expanse of an ocean.

The white cross of the school flag symbolizes "Love" and "Justice," and expresses the presence of "Truth" where love and justice meet.

The Tokai University Educational System is one of the largest general education and research institutions in Japan today. To seek mutual understanding and global peace through the education of, and interaction with, young scholars from around the world, we began accepting foreign students from an early stage and have consistently promoted Japanese-language education.

For more information, please visit: http://www.u-tokai.ac.jp/english/

Further information
Masato SATO, M.D., Ph.D.
Email: cellsheet(at)tsc.u-tokai.ac.jp
143 Shimokasuya, Isehara-shi, Kanagawa 259-1193
TEL: 0463-93-1121

http://cellsheet.med.u-tokai.ac.jp/en/index.html

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.